Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 88.2 to 52.5.
-
Busy address KBO
15 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Perrigo Belgium from Gent, company number BE0417132860, closed financial year 2025 with a result of € 9.7 million after tax. For that financial year Perrigo Belgium recorded revenue of € 44.6 million and equity of € 514.7 million. Compared with financial year 2023, the result moved from € 6.3 million to € 9.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 514.7 million
▲ 3% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9.7 million
▲ 53% vs 2023
Profit after tax over the fiscal year.
€ 66,069
▲ 8% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 256.7 million.
People and assets in 2025
52.5
▼ 33.8 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 7.2 million
▼ 38% vs 2023
€ 137,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 12.6 million
▲ 50% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 129 days on average.
€ 1.8 million
▼ 47% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2025 | Change 2023 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 45,283,870 | € 42,250,029 | € 49,916,370 | € 44,569,497 | ▼ 11% |
| Profit after taxes | € 1,029,392 | € 33,614,294 | € 6,313,515 | € 9,663,719 | ▲ 53% |
| Equity | € 458,270,010 | € 491,884,303 | € 498,197,819 | € 514,710,547 | ▲ 3% |
| Total debts | € 10,837,925 | € 10,536,242 | € 11,745,553 | € 14,402,637 | ▲ 23% |
| Cash | € 3,446 | € 2,878 | € 60,958 | € 66,069 | ▲ 8% |
| Land & buildings | € 251,411 | € 210,414 | - | - | |
| Retained profit | € 3,120,282 | € 233,902,061 | € 240,215,578 | € 256,728,306 | ▲ 7% |
| Bank debt | € 43,231 | € 43,231 | € 0 | € 0 | |
| Balance sheet total | € 469,786,025 | € 503,280,444 | € 510,448,332 | € 529,146,693 | ▲ 4% |
| Employees (FTE) | 93.6 | 88.2 | 86.3 | 52.5 | ▼ 33.8 |
Key figures of Perrigo Belgium, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Perrigo Belgium?
What happened at Perrigo Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Ronald van Workum stepped down as director. NBB
- Magali Verbraeken stepped down as director. NBB
- Anja van Winsberghe stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 9.7 million (▲ 53% vs 2023). Source: NBB ↗
- Ronald van Workum became a director. NBB
- Magali Verbraeken became a director. NBB
- Anja van Winsberghe became a director. NBB
- New establishment in Gent. KBO
In short
From € 1 million profit in 2021 to € 9.7 million profit in 2025.
Paid € 3.5 million in corporate taxes since 2021.
Best year ever: 2022, with € 33.6 million profit.
Pays suppliers within 129 days on average.
Management
The shares are held by Perrigo Capital NV (79.9%) and Perrigo Holding NV (20.1%). It owns 100% of Omega Pharma International, 100% of Omega Pharma Trading, 100% of Medgenix, 100% of Oce Bio and 47.8% of Omega Pharma Manufacturing GmbH & Co. KG itself.
Directors
According to the 2025 annual accounts
Magali Verbraeken
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Capital, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P., OMEGA PHARMA INTERNATIONAL, OMEGA PHARMA INNOVATION & DEVELOPMENT
since 2024 · until 2030
Anja van Winsberghe
Director
Also active at: MEDGENIX BENELUX, OMEGA PHARMA TRADING, Perrigo Capital, Perrigo Holding, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P., HRA PHARMA BENELUX +2 more
since 2023 · until 2029
since 2025 · until 2031
Shareholders
79.9%
20.1%
Participations
100%
100%
100%
Omega Pharma Manufacturing GmbH & Co. KG
47.8%
Establishments
Establishment units
Physical locations of this company
Gaston Crommenlaan 6 box 606
9050 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 15 companies are registered at this address.
All companies at this address →OMEGA PHARMA TRADING same network
€ 538,596 revenue · 2025
Perrigo Capital same network
€ 2.2 million revenue · 2025
Perrigo Holding same network
€ 48.4 million revenue · 2025
Perrigo Europe Invest same network
Oce-Bio same network
€ 4.1 million revenue · 2025
+10 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0417.132.860
- VAT number
- BE 0417.132.860
- Registered office
- Gaston Crommenlaan 6 bus 606, 9050 Gent
- Names & denominations
- Perrigo Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 May 1977
- Peppol
- Active · Active since 8 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Groothandel in andere consumentenartikelen, neg
Overige groothandel in consumentenartikelen, n.e.g.
Detailhandel in vaste, vloeibare en gasvormige brandstoffen, muv motorbrandstoffen
Overige detailhandel, niet in winkels en exclusief markt- en straathandel